What is Lucid Diagnostics?
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company dedicated to the early detection of esophageal precancer and cancer. The firm focuses specifically on patients suffering from gastroesophageal reflux disease (GERD), a demographic at elevated risk for esophageal adenocarcinoma, a condition characterized by high mortality rates. The company's core value proposition centers on its flagship product, the EsoGuard Esophageal DNA Test, which is utilized in conjunction with the EsoCheck Esophageal Cell collection device. This integrated diagnostic platform is designed to provide a non-invasive, highly accurate screening solution that aims to prevent deaths associated with esophageal cancer through timely clinical intervention. Incorporated in 2018 and headquartered in New York, the company functions as a key subsidiary of PAVmed Inc., benefiting from a broader ecosystem of medical innovation.
How much funding has Lucid Diagnostics raised?
Lucid Diagnostics has raised a total of $85.3M across 2 funding rounds:
Stock Offering
$70M
Stock Offering
$15.3M
Stock Issuance/Offering (2021): $70M, investors not publicly disclosed
Stock Issuance/Offering (2025): $15.3M, investors not publicly disclosed
Key Investors in Lucid Diagnostics
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Lucid Diagnostics?
With the recent capital deployment, Lucid Diagnostics is expected to prioritize the expansion of its commercial infrastructure and the broader adoption of its EsoGuard and EsoCheck platforms. The strategic focus will likely shift toward increasing clinical awareness among gastroenterologists and primary care providers, thereby enhancing the standard of care for at-risk GERD patients. Furthermore, the company is poised to continue its research and development efforts to refine its diagnostic accuracy and potentially broaden the application of its cell collection technology. As the firm moves into its next phase of growth, the emphasis will remain on achieving widespread clinical integration and demonstrating the long-term economic and health benefits of early esophageal cancer screening.
See full Lucid Diagnostics company page
